Pharmacological Validation of a Translational Model of Cocaine Use Disorder: Effects of D-amphetamine Maintenance on Choice Between Intravenous Cocaine and a Nondrug Alternative in Humans and Rhesus Monkeys
Overview
Authors
Affiliations
Drug self-administration procedures are the gold standard for laboratory research to study mechanisms of drug use disorders and evaluate candidate medications. However, preclinical-to-clinical translation has been hampered by a lack of coordination. To address this limitation, we previously developed homologous intravenous (IV) cocaine choice self-administration procedures in rhesus monkeys and humans, and then demonstrated their functional equivalence. The present studies sought to determine the sensitivity of these procedures to d-amphetamine maintenance. Three (N = 3) rhesus monkeys with histories of cocaine self-administration and 16 (N = 16) humans with cocaine use disorder completed the studies. Monkeys were maintained on IV d-amphetamine (0, 0.019, 0.037 and 0.074 mg/kg/h), and then completed 7 sessions during each condition in which they completed 9 choice trials to receive 0.14 mg/kg/injection IV cocaine (corresponding to 10 mg/70 kg in humans) or 10 food pellets under independent, concurrent progressive-ratio schedules. Humans were maintained on oral extended release d-amphetamine (0, 30 and 60 mg/day, corresponding to the lowest 3 doses in monkeys) and participated in 12 sessions in which they chose money ($6.00) or IV cocaine (0, 3, 10 and 30 mg/70 kg). Blood samples were taken to compare d-amphetamine plasma levels across species. In monkeys and humans, d-amphetamine reduced the number of cocaine choices and produced comparable blood levels at equivalent daily doses. d-Amphetamine had similar efficacy, though lower potency, at reducing choice for an equivalent cocaine dose in monkeys relative to humans. These coordinated studies support the utility of these procedures as a translational model for cocaine use disorder. (PsycInfo Database Record (c) 2020 APA, all rights reserved).
Allen M, Rahimi O, Johnson B, Cao J, Newman A, Nader M J Pharmacol Exp Ther. 2025; 392(1):100033.
PMID: 39892998 PMC: 11822870. DOI: 10.1124/jpet.124.002356.
Lile J, Shellenberg T, Babalonis S, Hatton K, Hays L, Rayapati A Psychopharmacology (Berl). 2024; 241(6):1227-1236.
PMID: 38383903 PMC: 11434229. DOI: 10.1007/s00213-024-06557-1.
Effects of naltrexone on amphetamine choice in rhesus monkeys and rats.
Robinson H, Moerke M, Banks M, Negus S Exp Clin Psychopharmacol. 2023; 31(6):1080-1091.
PMID: 37184942 PMC: 10788965. DOI: 10.1037/pha0000655.
Naltrexone-bupropion combinations do not affect cocaine self-administration in humans.
Regnier S, Stoops W, Lile J, Alcorn 3rd J, Bolin B, Reynolds A Pharmacol Biochem Behav. 2023; 224:173526.
PMID: 36805862 PMC: 10865090. DOI: 10.1016/j.pbb.2023.173526.
Rahimi O, Cao J, Lam J, Childers S, Rais R, Porrino L J Pharmacol Exp Ther. 2022; 384(3):372-381.
PMID: 36507847 PMC: 9976790. DOI: 10.1124/jpet.122.001363.